Advertisement

ADVERTISEMENT

Metastatic-Breast-Cancer

Conference Coverage
Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer
12/06/2021

Janelle Bradley

Janelle Bradley
The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.
The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.
The inclusion of...
12/06/2021
Journal of Clinical Pathways
Conference Coverage
Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases
12/06/2021

Janelle Bradley

Janelle Bradley
Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.
Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.
Palbociclib plus letrozole is...
12/06/2021
Journal of Clinical Pathways
News
Anti-HER2 Therapy Shown to Decrease Expression in Metastatic Breast Cancer
09/29/2021
Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.
Findings were shown at the virtual 2021 ESMO Congress to support anti HER2 therapy in early metastatic breast cancer as a method to alter the molecular profile and prognosis of mBC.
Findings were shown at the...
09/29/2021
Oncology
News
National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer
09/29/2021
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national...
09/29/2021
Oncology
Dr Gatti-Mays
Dr Gatti-Mays Discusses DESTINY-Breast03 Trial Results
09/29/2021
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.
Margaret Gatti-Mays, MD, MPH, The Ohio State University, discusses the phase 2 DESTINY-Breast03 trial, data for which were presented at the 2021 ESMO Congress.
Margaret Gatti-Mays, MD, MPH,...
09/29/2021
Oncology
Saranya Chumsri, MD
Videos
Dr Chumsri Discusses Real-World Outcomes of ICIs for HR+, HER2- Metastatic Breast Cancer
09/28/2021
Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.
Saranya Chumsri, MD, Mayo Clinic, FL, highlights outcomes from a real-world study of ICIs to treat HR+, HER2-, metastatic breast cancer with a high tumor mutational burden.
Saranya Chumsri, MD, Mayo...
09/28/2021
Oncology
Dr Punie
Clinical Videos
Kevin Punie, MD, Discusses Novel Therapy Significantly Improving QOL Over SOC in 2L+ mTNBC
09/24/2021
Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...
Dr Punie, UZ Leuven, Belgium, discusses new data from the Phase 3 ASCENT study of sacituzumab govitecan-hziy in patients with relapsed or refractory metastatic TNBC who received two or more prior systemic therapies, at least one of them for...
Dr Punie, UZ Leuven, Belgium,...
09/24/2021
Oncology
Kevin Punie, MD
Dr Punie Discusses First Treatment to Improve Survival in mTNBC
09/23/2021
Kevin Punie, MD, highlights new data from the phase 3 ASCENT study of sacituzumab govitecan-hziy, which were presented at the 2021 ESMO Congress.
Kevin Punie, MD, highlights new data from the phase 3 ASCENT study of sacituzumab govitecan-hziy, which were presented at the 2021 ESMO Congress.
Kevin Punie, MD, highlights new...
09/23/2021
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
November 1 ⁠–⁠ November 2
November 6 ⁠–⁠ November 8
NEI Congress
November 7 ⁠–⁠ November 10
WoundCon
November 8
ECS
November 8 ⁠–⁠ November 10
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use